A. Dose-Response Functions for Cancer Mortality and Incidence
As discussed in the main paper, the dose-response (DR) functions for brain cancer and leukemia from exposures to occupational magnetic fields (MF) were calculated by combining the original data from five electric utility studies. (1) For both cancers, logistic regression with a log-linear model was used with matched case-control data to estimate odds ratios, which Kheifets et al. called "relative risks" under the rare-disease assumption. The resulting relative risks (RR) have an exponential dependence on the worker's cumulative exposure C: RR = exp[βC] = RR C/ 10 (S1)
where RR′  exp(10) is the DR slope. These slopes are given in Table III of Annual mortality rates  M and incidence rates  I are calculated for a given cumulative MF exposure by multiplying the appropriate DR function (eqs. S1 or S3) with the corresponding baseline rate  0 :
The baseline incidence / mortality rates  M0 / I0 for cancer depend on age and are reported by the U.S. government as averages over five-year age spans from ages 0-5 to 100+ years. For occupational exposures, we start the cancer rate calculations with ages 20-25 (Table S1 ).
Derivation of 5-year Average Cumulative Exposures with a 1-year Lag Time
Because age-dependent cancer mortality and incidence rates are reported as averages over five-year spans, the lagged cumulative exposure for age span i: In order to calculate lifetime disease risks as sums of 5-year average mortality or incidence rates, we must also average the cumulative magnetic fields over the same 5- year age spans:
.
By inspecting Figure S-1, this integral for i=1 can be expressed as the area of triangle T 1 : Computations are more efficient if we use the iterative form of the expression above:
If B i is a constant B for an entire working career from ages 20-64 (i=1-9) and zero after retirement (i < 10), then:   
B. Lifetable Calculation of Excess Cancer Mortality and Incidence
The increased mortality / incidence rate from a history of TWA exposures {B(j)| j=1,i} can then be calculated by substituting the average lagged cumulative exposure C(i) (eq. S5) into the DR model (eq. S1):
The DR is then used to calculate the excess lifetime mortality rates attributable to a TWA magnetic field exposure. The calculation started with the government's life-table for the U.S. population. (2) In particular, we used the published values for the probability q 0i of dying from any cause during the i th five-year interval, the life expectancy e i at the interval's beginning, and the number of people l i surviving from a cohort of 100,000 at age 20 (Table S-I) .
To perform a life table calculation with a hazardous exposure, (3) we converted the published number of survivors l i to the survival function: S 0 (20,i) = l i / l [20] [21] [22] [23] [24] , which is the probability of a 20-year old worker surviving to start of the i th age interval. Next, the mortality probability q i over each interval is converted into the average annual mortality rate from all causes * 0 () M i  , using a relationship derived from the differential equation 
In the absence of exposure, the age-specific mortality rates from a cancer are then the number of workers surviving to interval's onset = 100,000 S 0 (20,i) multiplied by the probability of dying within the five-year span = q 0i multiplied by the fraction of the allcause mortality rate due to the cancer. The lifetime mortality rate from the cancer in the absence of MF exposures can now be calculated:
where the sum is from ages 20-24 to 100+, the last age group in the published life table. 
8
The next step in the calculation is mortality rates with magnetic field exposures. The baseline rates from all causes (eq. S7) are adjusted for the excess death rates for both brain cancer and leukemia in each time period (eq. S6):
Then, the age-specific probabilities of death with MF exposures are derived by rearranging eq. S7 and replacing the annual death rates with eq. S9:
The survival function has a similar adjustment for the additional cancer deaths:
Paralleling eq. S8, the lifetime mortality rate from a particular cancer for exposed workers is now:
For a given history of 5-year TWA exposures over a working career, a spreadsheet (Table   S -I) calculates the numbers of excess cancer cases across age strata and, from this, the lifetime excess mortality risks M x (B) = M(B) -M 0 from brain cancer and leukemia.
To calculate the excess cancer incidence, the results comparable to life-table formulas are:
from which the lifetime excess incident rates: I x (B) = I(B) -I 0 can be calculated for brain cancer and leukemia as a function of the TWA magnetic field.
Baseline Mortality and Incidence Rates Corrected for U.S. MF Exposures
Age-specific cancer mortality and mortality rates M/I (i)  can be obtained from National
Center for Health Statistics (NCHS) (5) where p n (i) is the proportion of workers in age group i with cumulative exposure C n (i).
However, the best available MF data for the general working population are not cumulative exposures but measurements of the TWA by a 1000-person randomized surveillance study in the U.S. (7) To get baseline (no-exposure) cancer rates to use in eq. S6 and the formulas that follow, we assume that the NIOSH exposure scenario applies to all workers in the U.S. Therefore, the constant exposure formulas for the cumulative exposure in Section A.1 can be substituted into eq. 8, and solved for the no-exposure rates as a function of the published rates. For ages 25-64 (i=2-9), for example, the baseline rates are:
where p n is now the proportion of workers with mean TWA exposure B n .
To use this equation, we derived a categorical MF distribution {p n , B n } from the published percentiles Pn for n=1,5,10,25,50 etc. (7) as shown in Table S This distribution is approximately log-normal because its median P50 = 0.099 T is closer to the geometric mean = 0.103 T than to the arithmetic mean = 0.173 T.
Therefore, the mean exposure for a category between two successive percentiles Pn 1 and The proportion of workers in this category is p n = [n 2 -n 1 ]/100. The mean exposures for the tails of the distribution (< P1 and > P99) are the expectation values of B from a lognormal distribution with the above geometric mean and the measured geometric standard deviation = 2.57. (7) The resulting MF distribution {p n , B n } is then substituted in eq. S15 in order to obtain baseline incidence and mortality rates for the lifetable calculations (Section B).
C. Calculating Disability-adjusted Life Years (DALY)
DALYs are calculated as the sum of the years of life lost due to premature mortality (YLL) in the population and the adjusted "years lived with disability" (YLD) for incident cases of the health condition:
First, YLL is calculated from the published age-specific life-expectancy e i and the excess cancer deaths for all five-year age intervals:
where the sum goes up to 90 years of age.
Next, YLD are calculated from the age-specific excess incidence I x (I,B) (eq. S13) for brain cancer and the four major sub-types of leukemia (acute and chronic myeloid leukemia; acute and chronic lymphocytic leukemia), plus all other leukemia sub-types grouped together. For each of these cancer sub-types, the formula for YLD then combines the incidence rates, the probability of surviving with the cancer S p , and disability weights DW j provided by a burden of disease study in Victoria, Australia: (8, 9) 
where the index j=1 … J goes over time intervals t j from the cancer's diagnosis to its remission and the index k=1 … K goes from diagnosis to premature death from the cancer.
Discounted DALYs
With a discount rate = d, the discounted YLL and YLD are:
To re-capitulate all the steps in this preceding sections, Table S-II compiles a calculation for a single age range and TWA = 1 T.
D. Quantification of Uncertainties
We first identified all sources of variability and error in our risk metrics and when possible, quantified the uncertainty of the input variables for the risk calculations (Table   III in the main paper). The quantified uncertainties fall into two groupsthe DR parameters and exposure distribution whose statistical properties can be rigorously characterized, and the parameters for which we only have a range of possible values (the monetary value of the DALY and the posterior probability). For the DR parameters, our uncertainty analysis consisted of a rigorous propagation of errors, (11) which results in 95% confidence limits and one-tailed hypothesis tests. For the more poorly characterized parameters, our sensitivity analysis also used the propagation of error formulas, but with approximate standard errors derived from the range of possible values. The limits derived from these more approximate error estimates have been called uncertainty limits. (12) For the sensitivity analysis, random errors are quantified as the variable's standard error (SE), and systematic errors are given as the bias
(where x true is an estimate of the true value and x is the mean used in our primary metric calculations). For the DR . **Calculated with the above incidence formulas using the appropriate annual U.S. rates as input parameters, the random errors from chance and inter-study variability among the five electric utility studies (1) can be quantified from the 95% confidence limits on the relative risks (Table III) . Since the pooling of the five epidemiologic databases is a large sample (291 cases of brain cancer and 348 cases of leukemia), normal distributions can be assumed for the logs of the relative risks in the dose-response functions: ln RR/10   (eq. 1) and ln RR hi C   hi (eq. 4). Using the published confidence levels on the relative risks, the standard errors for these beta coefficients can then be calculated from:
The biases in these DR coefficients could be quantified in two cases -first for the "single company bias" where the electric utility studies (1) 
where  obs and T obs are the values from the combined electric utility studies, (1) and T true is the U.S. average. The results are in Table S-II. Another quantifiable bias comes from the reported synergism between elevated occupational MFs and selected chemicals in a brain cancer study. (14) For lead, mercury, pesticides/herbicides, solvents, and arsenic, the bias  in the brain cancer risks for the highest exposure category ( hi ) can be estimated from the difference between the significant s with and without that chemical exposure. These bias estimates for  hi are extended to the DR  by using the formula for the brain cancer's exponential-linear transition point (eq. S3): 51.2 T-yr = 10 T-yr ln RR hi C / ln RR =  hi / . By assuming that the chemical exposure does not change the transition point, we get the bias in the DR slope as:  =  hi / 51.2 T-yr for each chemical (Table S-III) . For the metrics like the population attributable fraction and the U.S. disease burden, the bias  c for each chemical c is weighted by the proportion of workers exposed p c , which we estimate from the proportion of cases p c = N c / N total exposed in Navas-Acien et al. (14) (Table S-III) .
We also conducted a sensitivity analysis on the posterior probability, the DALY's value and the discount rateparameters with large uncertainties but undetermined statistical properties. A simple sensitivity analysis with the extremes values for these parameters (Table IV) gives bounds on the metrics ranging from 2-830% of the predicted values. To obtain more realistic limits, we treated the extremes in Table IV as 95% confidence limits on random variables distributed normally or log-normally so that expanded uncertainty limits could be calculated with the same methods used with the true random errors (Section G below). For the value of a statistical life year (VSLY), our chosen value of $100,000 and the extremes of $24,777 (15) and $482,487 (16) suggest a log-normal distribution, so its approximate "standard error" (designated SE ) can be calculated from eq. S24 (Table S- 
E. Propagation of Errors for the Economic Burden
Given estimates for the various sources of uncertainty, we used the derivative method for the propagation of errors (11) to obtain confidence limits and uncertainty limits on the expected values of the metrics in Table II (except for the action level which is discussed in Section I). With this method, the SE of any metric Z which depends on multiple variables x={x 1 , x 2 , …} is given by:
where  jk is the correlation between two independent variables. Assuming the errors in the metric Z are normally distributed, the 95% confidence limits for the mean metric value equal   0.975 Z Z z SE x  . The p-value from one-tailed tests is:
For the metric's expectation value P z from the posterior probability of causality P, the confidence limits are
, and the p-value is unchanged.
For each source of bias in variables x i , the calculated value for metric Z can be corrected to our approximation to its true value:
The 95% confidence limits on the corrected metric value =   true 0.975 Z Z z SE x  have been called uncertainty limits on   Z x when the bias correction lacks rigor. (12) Likewise, uncertainty limits on the bias-adjusted expectation value are   true 0.975 Z P Z z P SE x  . Since the data for the single company bias and chemical biases are less robust than the other input data, the metric values corrected for these biases in this Supplemental Online Material is not reported in the main paper, which only gives means with their 95% confidence limits and uncertainty limits.
Note: By definition, (12) an uncertainty limit that violates some physical or biological principle is replaced by the rational limit in all reports. For DALY(B) or b $ (B), negative values are irrational because they imply MFs prevent cancer. When their lower bound from the uncertainty limit formula (above) is negative, the lower uncertainty limit is therefore reported as zero (i.e. no risk).
The partial derivatives in eqs. S25 -S26 were calculated in two ways. First, they were calculated analytically with Mathematica software (Wolfram Media, Champaign, IL) after first replacing the iterative dependence of the survival function on the DR parameters (eq. S11) with the exposure-independent survival function S 0 (0,i). To test this assumption, the partial derivatives of YLL were also calculated by finite differences, (17) using our spreadsheets to change each independent variable by 10%. The two approaches agreed within 7%.
Since these derivatives depend on the TWA magnetic field, the uncertainty calculations are done for 0.05, 1.0 and 50 T (Table S-III). We omitted YLD in the derivatives of the economic burden since it is only 6-7% of YLL (Tables IV and V) . All the independent variables in Table S -III would appear to be uncorrelated except for the betas for the continuous DR and the highest exposure category with the same cancer. In eq. S25, the correlation coefficient ρ between  and  hi were assumed to be 0.9 for both brain cancer and leukemia.
Next, the uncertainties in the posterior probability and the value of the statistical life year (VSLY) were treated as random errors whose variances could be propagated to the expectation value of the discounted economic burden:
where the log transform makes the uncertainty in VSLY log-normal. Then, the approximate standard error b SE $ for the economic burden's expectation value can be derived from eq. S25 and S27 by assuming the uncertainties are uncorrelated:
where the standard error for the DALY is obtained rigorously from eq. S25. 
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The results of the sensitivity analysis for the expectation values of the monetary burdens from a fixed TWA magnetic field exposure are summarized in Table S-III. The appropriate chemical bias depends on the chemical(s) observed on the particular job. As an illustration, these summary results give uncertainty limits only for mercurythe chemical with the highest risk and therefore the greatest impact on the uncertainty. For the slopes, linear regressions were performed on the TWA-specific limits in Table S-III, giving the confidence and uncertainty limits reported in Table VI of the main paper.
From intervals, which makes their lower uncertainty limit zero. The single company bias reduces the upper uncertainty limit by 41% of the mean. A chemical that reportedly increase brain cancer risks increases the upper uncertainty limit by 30 -50% of the mean for each chemical present at a work location. For the lower uncertainty limit to be above $0, a worker would have to be exposed to a 1 T MF, mercury, arsenic, lead and solvents. 
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F. The Precautionary Level and its Uncertainty Analysis
The precautionary level (PL) is determined by setting the expectation values of either the excess incidence I x (B) or the discounted economic burden EB(B) to a de minimis value.
For an arbitrary metric Z(B), this relationship is:
where Z dm is the metric's de minimis value. Since the metrics are highly non-linear functions of B (Section B), an analytic solution of the eq. S30 for PL appears impossible.
For accurate determinations, candidate PLs were therefore calculated by trial-and-error with the lifetable spreadsheet until the metric equaled a postulated de minimis value within three significant figures.
Since the PL is the inverse of the metrics analyzed in Section G, a new approach is needed for its sensitivity analysis. First, an analytic form of PL was determined approximately by taking first taking a power series expansion of Z(B) about B = 0:
where U and V depend on the DR parameters and the MF exposure distribution. Then,
Since the errors in the s and P are normally distributed, the errors in the AL belong to an inverse normal distribution, so its confidence and uncertainty limits must be derived from this little-known function. (21) To derive these confidence limits, we first follow eq. S32 in defining the variability in PL by a random variable y = Z dm /x. This second random variable x belongs to a normal distribution with mean = P f and variance  2 . Since y is the inverse of x, it has the probability density function of an inverse normal distribution: (21)   The 95% confidence limits on the AL are given by: 
We now note that  PL in the above denominator is the first term in a power series of the S30). Therefore, eq. S33 can be re-written:
In other words, the lower confidence level and mean of the action level would be inversely proportional to those of the metric's expected value, except that lower and upper confidence levels are switched in eq. S34a. Likewise,
Thus, upper and lower limits on the action level follow simply from the confidence and uncertainty limits on Z derived by the methods in section G.
According to eq. S34b, a negative, non-significant lower limit for Z means a negative UCL[PL], which is less than LCL[PL]. This non-sense result derives from the fact that PL   as Z  0, so the PL is undefined for negative Z. In these cases, we report the upper limit on PL as infinity.
Furthermore, the null hypothesis in this case is PL =  (i.e. an intervention is never needed). To avoid this infinity, significant tests for the PL were performed instead on the null hypothesis: Z(PL) < 0.
Finally, consider biases in Z and their propagation to PL. As in section G, define a bias by:
From PL's definition (eq. S30), the bias in the PL is given by: 
This result can be applied to the single company bias and chemical biases which were quantified in Section F. 
G. Abbreviations and Units
